We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03681483
Recruitment Status : Active, not recruiting
First Posted : September 24, 2018
Last Update Posted : December 2, 2022
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Chugai Pharma USA
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Brief Summary:
The purpose of this study is to test the safety of RO5126766 at different doses to find out what effects, if any, it has on people with advanced lung cancer who have previously received treatment with a PD-1 or PD-L1 inhibitor.

Condition or disease Intervention/treatment Phase
Advanced Non-small Cell Lung Cancer Drug: RO5126766 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Single arm, open label, multi-institution study of RO5126766 (CH5127566) in patients with KRAS mutant NSCLC.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Trial of RO5126766 (CH5126766) in Patients With Advanced KRAS-Mutant Lung Adenocarcinomas
Actual Study Start Date : October 31, 2018
Estimated Primary Completion Date : September 2023
Estimated Study Completion Date : September 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: RO5126766 (CH5126766)
The study will begin with a standard 3+3 design. The study will enroll 3 patients at the previously identified MTD15 (4mg two times per week on days 1 and 4). The period of evaluation for dose limiting toxicity will be through completion of cycle 1. If ≤1 of the 3 initial patients at the proposed dose experience a DLT, then 3 additional patients will be enrolled for a total of 6 planned patients at that dose level. Otherwise, 3 patients will be enrolled at dose level -1. If ≤ 1 of these patients experience a DLT, then 3 additional patients will be enrolled at the same dose level. If more than 1 patient experiences a DLT in dose level -1, the study will be terminated.
Drug: RO5126766
RO5126766 (CH5126766) is given 4mg twice weekly (Day 1 and Day 4 of each week) and should be taken by mouth on an empty stomach, either one hour before or two hours after a meal.
Other Name: (CH5126766)




Primary Outcome Measures :
  1. The maximum tolerated dose (MTD) [ Time Frame: 1 year ]
    will be defined as the highest dose level at which ≤ 1 of 6 patients experienced a DLT.The NCI Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE) will be used to grade toxicities during the trial. DLTs are defined as any toxicity occurring during the first cycle of treatment (i.e. 4 weeks), excluding toxicites clearly related to disease progression or disease-related processes.

  2. overall response rate (dose expansion) [ Time Frame: 1 year ]
    by RECIST 1.1



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically proven diagnosis of advanced NSCLC
  • Documented presence of KRAS mutation
  • Prior treatment with a PD-1/L1 inhibitor. Patients who were deemed not eligible for therapy with a PD-1/L1 inhibitor by their treating physician will also be eligible in the dose expansion phase.
  • Prior treatment with chemotherapy
  • Able to take oral medications
  • Measurable and/or evaluable disease (RECIST 1.1) indicator lesion not previously irradiated
  • Karnofsky performance status (KPS) ≥ 70% (ECOG of 0 or 1 also acceptable)
  • Age≥ 18 years old
  • Hematological and biochemical indices within the ranges shown below Hematological and biochemical indices within the ranges shown below (These measurements must be performed within two weeks [Day 14 to Day 1] before the patient is entered into the trial).

    • AST, ALT ≤ 2.5 x ULN - Total bilirubin ≤ 1.5 x ULN -Albumin≥2.5g/dL
    • Creatinine < 1.5 x ULN OR calculated creatinine clearance ≥50mL/min
    • Absolute neutrophil count (ANC) ≥ 1,200 cells/mm3
    • Hemoglobin ≥9.0 g/dL
    • Platelets ≥100,000/mm^3.
  • A negative serum pregnancy test obtained within two weeks prior to the administration of the study drug in all women of child bearing potential

Exclusion Criteria:

  • Patients with symptomatic brain metastasis requiring escalating doses of steroids
  • Patients with grade 2 or greater diarrhea prior to study initiation despite maximal medical management
  • History of any bowel disease including abdominal fistula, gastro-intestinal perforation
  • History of acute pancreatitis within 1 year of study entry or history of chronic pancreatitis
  • History of or ongoing alcohol abuse that, in the opinion of the treating physician, would compromise compliance or impart excess risks associated with study participation.
  • Pregnant or lactating women
  • Any type of systemic therapy (chemotherapy or experimental drugs) within 3 weeks of starting treatment on protocol (within 6 weeks for for nitrosoureas and mitomycin C)
  • Radiotherapy within 2 weeks of starting treatment on protocol
  • Prior treatment with MEK, RAF, or ERK inhibitor(s)
  • Significant uncontrolled or active cardiovascular disease, specifically including, but not restricted to:

    • History of clinically significant (as determined by the treating physician) atrial arrhythmia
    • Any ventricular arrhythmia
    • History of congenital long QT syndrome.
    • Abnormal QTc (≥ 450 msec in males and ≥ 470 msec in females)
    • Ejection fraction ≤ 50% as assessed by echocardiogram
    • Concurrent congestive heart failure
    • Prior history of class III/ IV heart failure (New York Heart Association [NYHA]
    • Myocardial infarction within the last 6 months
    • Unstable angina or severe obstructive pulmonary disease
  • Patients with baseline risk factors for central serous retinopathy or retinal vein occlusion such as evidence of new optic disc cupping, evidence of new visual field defects, and intraocular pressure >21 mmHg Uncontrolled hypertension (Diastolic blood pressure > 100 mmHg; Systolic blood pressure > 150 mmHg).
  • History of central serous retinopathy or retinal vein occlusion
  • History of prior malignancy within 2 years that requires/ed treatment. Patients who are considered NED from a malignancy may be considered on a case by case basis.
  • Known active hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infections
  • Patients exposed to CYP3A4 inhibitors within 7 days prior to the first dose and CYP3A4 inducers 7 days prior to the first dose. RO5126766 (CH5126766) is metabolised mainly by CYP3A4 therefore concomitant administration of strong inhibitors and inducers of cytochrome p450 3A4 enzymes is forbidden during study treatment (for a complete list please see Appendix A).
  • Any other condition that, in the opinion of the investigator, may compromise the safety, compliance of the patient, or would preclude the patient from successful completion of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03681483


Locations
Layout table for location information
United States, Florida
Miami Cancer Institute
Miami, Florida, United States, 33143
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
United States, Pennsylvania
Lehigh Valley Health Network
Allentown, Pennsylvania, United States, 18103
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Chugai Pharma USA
Investigators
Layout table for investigator information
Principal Investigator: Gregory Riely, MD, PhD Memorial Sloan Kettering Cancer Center
Additional Information:
Layout table for additonal information
Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT03681483    
Other Study ID Numbers: 18-285
First Posted: September 24, 2018    Key Record Dates
Last Update Posted: December 2, 2022
Last Verified: December 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Memorial Sloan Kettering Cancer Center:
RO5126766 (CH5126766)
KRAS-Mutant
18-285
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases